Efficacy of dextran solutions in vascular surgery

Vascular and Endovascular Surgery

Volumn 38, Issue 6, 2004, Pages 483-491

  Abir, Farshad ^a,b   Barkhordarian, Siamak ^a,b   Sumpio, Bauer E ^a,b  

^a Section of Vascular Surgery ^*

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN 40; DEXTRAN 70; HEPARIN; POLITEF;

ACUTE KIDNEY FAILURE; ANAPHYLACTIC SHOCK; ANASTOMOSIS; ANTICOAGULANT THERAPY; ARTERIOVENOUS FISTULA; BLEEDING; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; COMPOSITE GRAFT; CONGESTIVE HEART FAILURE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; EMBOLISM; EVIDENCE BASED MEDICINE; FLOW RATE; GLOMERULUS FILTRATION RATE; GRAFT PATENCY; HEART ATRIUM THROMBOSIS; HEMODILUTION; HUMAN; LUNG EDEMA; LUNG EMBOLISM; MEDLINE; NONHUMAN; PROSPECTIVE STUDY; REVIEW; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; UMBILICAL VEIN; VASCULAR SURGERY; VEIN THROMBOSIS; VOLUME OVERLOAD;

ANTICOAGULANTS; DEXTRANS; ENDARTERECTOMY, CAROTID; HUMANS; KIDNEY FAILURE, ACUTE; PULMONARY EDEMA; VASCULAR SURGICAL PROCEDURES;

EID: 10344249380     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/153857440403800601     Document Type: Review

References (46)

1. Erdtmann M, Keller R, Baumann H: Photochemical immobilization of heparin, dermatan sulphate, dextran sulphate and endothelial cell surface heparan sulphate onto cellulose membranes for the preparation of athrombogenic and antithrombogenic polymers. Biomaterials 15:1043-1048, 1994.
2. Zeerleder S, Mauron T, Lammle B, et al: Effect of low-molecular-weight dextran sulfate on coagulation and platelet function tests. Thromb Res 105:441-446, 2002.
3. Muzzafar TZ, Stalker AL, Bryce WAJ, et al: Dextran and fibrin morphology. Nature 238:288-290, 1972.
4. Carr ME, Gabrile DA: Dextran induced changes in fibrin fiber size and density based on wavelength dependence of gel turbidity. Macromolecules 13:1473, 1980.
5. Collet JP, Soria J, Mirshahi M, et al: Dusart syndrome: A new concept of the relationship between fibrin clot architecture and fibrin clot degradability: Hypofibrinolysis related to an abnormal clot structure. Blood 82:2462-2469, 1993.
6. Barshtein G, Tamir I, Yedgar T: Red blood cell rouleaux formation in dextran solution: Dependence on polymer conformation. Eur Biophys J 27:177-181, 1998.
7. Victorino GP, Newton CR, Curran B: Dextran modulates microvascular permeability: Effect in isotonic and hypertonic solutions. Shock 19:183-186, 2002.
8. Muir JJ, Church EJ, Weinmeister KP: Epidural hematoma associated with dextran infusion. South Med J 96:811-814, 2003.
9. Niklasson PM, Blomback M, Lundbergh P, et al: Thrombocytopenia and bleeding complications in severe cases of meningococcal infection treated with heparin, dextran 70, and chlorpromazine. Scand J Infect Dis 4:183-191, 1972.
10. Prist R, Rocha e Silva M, Velasco IT, et al: Pressure-driven hemorrhage: A new experimental design for the study of crystalloid and small-volume hypertonic resuscitation in anesthetized dogs. Circ Shock 36:13-20, 1992.
11. Ring J, Messmer K: Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1:466-469, 1977.
12. Ellingson TL, Aboulafia DM: Dextran syndrome: Acute hypotension, noncardiogenic pulmonary edema, anemia and coagulopathy following hysteroscopic surgery using 32% dextran 70. Chest 111:513-518, 1997.
13. Biesenbach G, Kaiser W, Zazgornik J: Incidence of acute oligoanuric renal failure in dextran-40-treated patients with acute ischemic stroke stage III or IV. Ren Fail 19:69-75, 1997.
14. Zwaveling JH, Meulenbelt J, van Xanten NHW, et al: Renal failure associated with the use of dextran-40. Neth J Med 35:321-326, 1989.
15. Siegel DB: Use of anticoagulants in replantation and elective microsurgery. Microsurgery 12:277-280, 1991.
16. Novey HS, Pahl M, Haydik I, et al: Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy 72:224-228, 1994.
17. Renck H, Ljungstrom KG, Hedin H, et al: Prevention of dextran-induced anaphylactic reactions by hapten inhibition. III. A Scandinavian multicenter study on the effects of 20 mL dextran 1, 15%, administered before dextran-70 or dextran-40. Acta Chir Scand 149:355-560, 1983.
18. Fishbane S, Ungureanu V, Maesaka J, et al: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28:529-534, 1996.
19. Haught WH, Sokol M, Kerensky RA, et al: Decrease in hematocrit after coronary stent placement and dextran therapy. Am J Cardiol 76:314-315, 1995.
20. Dubick MA, Wade CE: A review of the efficacy and safety of 7.5% NaCl/6% dextran-70 in experimental animals and in humans. J Trauma 36:323, 1994.
21. Wade CE, Grady JJ, Kramer GC: Efficacy of hypertonic saline dextran fluid resuscitation for patients with hypotension from penetrating trauma. J Trauma 54:S144-S148, 2003.
22. Clagett GO, Reisch JS: Prevention of venous thromboembolism in general surgical patients: Results of a meta-analysis (Review). Ann Surg 208:227-240, 1988.
23. Ljungstrom KG: Prophylaxis of postoperative thromboembolism with dextran-70: Improvements of efficacy and safety. Acta Chir Scand 514(suppl):1-40, 1983.
24. Gruber UF, Saldeen T, Bkop T, et al: Incidence of fatal postoperative pulmonary embolism after prophylaxis with dextran-70 and low-dose heparin: An international multicenter study. Br Med J 280:69-72, 1980.
25. Rutherford RB, Jones DN, Bergentz S-E, et al: The efficacy of dextran-40 in preventing early postoperative thrombosis following difficult lower extremity bypass. J Vase Surg 1:765-773, 1984.
26. Aberg M, Hedner V, Bergentz SE: Effect of dextran on factor VIII and platelet function. Ann Surg 189: 243-247, 1979.
27. Aberg M, Bergentz SE, Hedner V: The effect of dextran on the lysability of ex vivo thrombi. Ann Surg 181:342-345, 1975.
28. Matthiasson SE, Lindblad B, Matzch T, et al: Study of the interaction of dextran and enoxaparin on heamostasis in humans. Thromb Haemost 72:722-727, 1994.
29. Shoenfeld NA, Eldrup-Jorgensen J, Connolly R, et al: The effect of low molecular weight dextran on platelet deposition onto prosthetic materials. J Vasc Surg 5:76-82, 1987.
30. Katz SG, Kohl RD: Does dextran 40 improve the early patency of autogenous infrainguinal bypass grafts? J Vase Surg 28:23-26, 1998.
31. Rothkopf DM, Chu B, Bern S, et al: The effect of dextran on microvascular thrombosis in an experimental rabbit model. Plast Reconstr Surg 92:511-515, 1993.
32. Zhang B, Wieslander JB: Dextran's antithrombotic properties in small arteries are not altered by low-molecular-weight heparin or the fibrinolytic inhibitor tranexamic acid: An experimental study. Microsurgery 14:289-295, 1993.
33. Salemark L, Knudsen F, Dougan P: The effect of dextran 40 on patency following severe trauma in small arteries and veins. Br J Plast Surg 48:121-126, 1995.
34. Frost-Arner L, Bergqvist D: Effects of hypertonic saline-dextran solution on regional blood flow and thrombogenicity in PTFE grafts in the vena cava of the rabbit. Eur J Vasc Endovasc Surg 19:12-20, 2000.
35. Waibel P: Antikoagulation in der Gefässchirurgie. Vasa 5:107,110, 1976.
36. Rutherford RB, Jones DN, Bergentz S-E, et al: Factors affecting the patency of infrainguinal bypass. J Vasc Surg 1988;8:236-246.
37. Kluge TH, Rø JS, Fretheim B, et al: Thrombosis prophylaxis with dextran and warfarin in vascular operations. Surg Gynecol Obstet 135:941-944, 1972.
38. Ferraboli R, Malheiro PS, Abdulkader RCRM, et al: Anuric Case Report: Vos et al: Dextran-Induced Acute Renal Failure acute renal failure caused by dextran 40 administration. Ren Fail 19:303-306, 1997.
39. Ross S, Ebert R: Microelectrophoresis of blood platelets and the effect of dextran. J Clin Invest 38:135-139, 1955.
40. Sawyer RB, Moncrief JA: Dextran specificity in thrombus inhibition. Arch Surg 90:562-566, 1965.
41. Carlin G, Saldeen T: On the interaction between dextran and the primary fibrinolysis inhibitor alpha-2-antiplasmin. Thromb Res 19:103-110, 1980.
42. Guant MR, London NJM, Smith J, et al: Early diagnosis of postoperative carotid occlusion using transcranial Doppler ultrasound. J Vasc Surg 20:1004-1005, 1994.
43. Levi CR, Stork JL, Chambers BR, et al: Dextran reduces embolic signals after carotid endarterectomy. Ann Neurol 50:544-547, 2001.
44. Hayes PD, Lloyd AJ, Lennard N, et al: Transcranial Doppler-directed Dextran-40 therapy is a cost-effective method of preventing carotid thrombosis after carotid endarterectomy. Eur J Vasc Endovasc Surg 19:56-61, 2000.
45. Naylor AR, Hayes PD, Allroggen H, et al: Reducing the risk of carotid surgery: A 7-year audit of the role of monitoring and quality control assessment. J Vasc Surg 32:750-759, 2000.
46. Lennard N, Smith JL, Hayes P, et al: Transcranial Doppler-directed dextran therapy in the prevention of carotid thrombosis: Three-hour monitoring is as effective as six hours. Eur J Vasc Endovasc Surg 17:301-305, 1999.